This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

OncoMed Pharmaceuticals Announces Second Quarter 2013 Financial Results

Company Completes $94 Million IPO in July Vantictumab Dose Escalation Progress Triggers $10 Million Milestone in August

REDWOOD CITY, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results for the second quarter of 2013. The results are the first operating results the company is reporting as a public company.

On July 23, 2013, the company successfully closed the initial public offering (IPO) of its common stock, raising proceeds, net of underwriter discounts and commissions but prior to the payment of remaining offering expenses payable by the company, of $87.3 million dollars, which included the sale of shares to the underwriters upon the full exercise of their option to purchase additional shares of common stock. Pro forma cash as of July 31, 2013 was $140 million.  The company also announced today that it had earned in August a $10 million clinical milestone related to the Phase 1 dose escalation in its vantictumab program, which is part of its collaboration with Bayer Pharma AG.

According to OncoMed's Chairman, President and Chief Executive Officer, Paul J. Hastings, "The successful completion of our IPO positions us to advance our broad research and development pipeline. We continue to see progress in our robust discovery and preclinical pipeline as well as with our five OncoMed-discovered anti-cancer stem cell therapeutics that are in clinical trials."

Second Quarter and Recent Corporate Highlights:

  • Initiated in July 2013 new Abraxane/Demcizumab/Gemcitabine cohorts of Phase 1b testing in patients with pancreatic cancer
  • Initiated in May 2013 enrollment of the anti-Notch2/3 Phase 1b/2 PINNACLE trial in small cell lung cancer, which triggered an $8 million advance payment from GlaxoSmithKline (GSK)
  • Presented in June 2013 first-in-human clinical data from vantictumab at the ASCO 2013 Annual Meeting
  • Made in April 2013 five poster presentations and one plenary oral presentation at the AACR Annual Meeting 2013 with data from five OncoMed anti-CSC programs
  • Completed in July 2013 successful initial public offering raising $94 million in gross proceeds
  • Received in May 2013 issued U.S. patent covering both anti-Notch1 composition of matter and methods of treating cancer with anti-Notch1
  • Received in August 2013 issued U.S. patent covering methods of treating cancer with vantictumab
  • Achieved in August 2013 a $10 million milestone related to the Phase 1 dose escalation of vantictumab through its collaboration with Bayer

Second Quarter 2013 Financial Results and Initial Public Offering

OncoMed ended the second quarter with a cash balance of $56.5 million. Subsequently in July, the company closed an initial public offering of its common stock selling an aggregate of 5,520,000 shares of common stock at a public offering price of $17.00 per share, including 720,000 shares pursuant to the exercise by the underwriters of an option to purchase additional shares of common stock.  Net proceeds were approximately $87.3 million, after deducting underwriting discounts and commissions but prior to the payment of remaining offering expenses payable by OncoMed. The pro forma cash following the offering at July 31, 2013 was $140 million.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs